Designing Novel Compounds for the Treatment and Management of RET-Positive Non-Small Cell Lung Cancer—Fragment Based Drug Design Strategy

Rearranged during transfection (RET) is an oncogenic driver receptor that is overexpressed in several cancer types, including non-small cell lung cancer. To date, only multiple kinase inhibitors are widely used to treat RET-positive cancer patients. These inhibitors exhibit high toxicity, less effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramesh, Priyanka, Veerappapillai, Shanthi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911629/
https://www.ncbi.nlm.nih.gov/pubmed/35268691
http://dx.doi.org/10.3390/molecules27051590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911629/
https://www.ncbi.nlm.nih.gov/pubmed/35268691
http://dx.doi.org/10.3390/molecules27051590

Ejemplares similares